Agamree (vamorolone)

The first dissociative steroid approved for DMD, designed to provide the anti-inflammatory benefits of corticosteroids while reducing the bone loss, growth stunting, and behavioral side effects that make traditional steroids difficult for boys with DMD.

Vamorolone binds to the same glucocorticoid receptors as prednisone and deflazacort but activates them differently. It suppresses the NF-kB inflammatory pathway (which drives muscle damage in DMD) without fully activating the gene transcription pathways responsible for bone loss, weight gain, and growth suppression. This 'dissociative' mechanism preserves the therapeutic anti-inflammatory effect while reducing the most problematic steroid side effects.

Side effects are generally milder than traditional corticosteroids. Common effects include cushingoid appearance, weight gain, and increased appetite, though studies show better bone density preservation and growth trajectory compared to prednisone. Behavioral effects and adrenal suppression can still occur. Blood pressure and adrenal function should be monitored. Like other corticosteroids, Agamree raises the risk of infections, which can be serious or even fatal and may be harder to notice, so tell the doctor about any signs of infection. Live or live-attenuated vaccines should not be given during treatment; they should be given at least 4 to 6 weeks before starting. Do not stop Agamree suddenly after more than 1 week of use; the dose must be lowered slowly. The label also warns about high blood sugar, salt and potassium changes, stomach or bowel tears, eye problems such as cataracts and glaucoma, bone loss and fractures, effects on growth and development in children, muscle weakness (myopathy), Kaposi's sarcoma, blood clots, and rare severe allergic reactions (anaphylaxis).

Taken orally once daily as a liquid suspension at 6 mg/kg/day. It is best taken with a meal. The maximum daily dose is 300 mg for patients who weigh more than 50 kg, and doctors may lower the dose to 2 mg/kg/day if needed. Available as an oral suspension for ease of dosing in young children.

Yes, Vamorolone (Agamree) is FDA approved (2023) for the treatment of Duchenne Muscular Dystrophy.

Vamorolone is a dissociative corticosteroid, meaning it selectively activates the anti-inflammatory parts of the glucocorticoid receptor signaling pathway while reducing activation of the pathways responsible for the worst steroid side effects. Traditional steroids like prednisone and deflazacort activate both pathways equally, which is why they cause bone loss, weight gain, growth suppression, and behavioral changes. In its main trial, vamorolone improved motor function compared with placebo, and boys on it did not show the drop in height percentile or bone turnover markers seen with prednisone. It is still a corticosteroid and carries steroid warnings.

Yes, vamorolone is designed as an alternative to traditional corticosteroids for DMD. In the VISION-DMD trial it improved motor function compared with placebo, and boys on it did not show the drop in height percentile seen with prednisone. Some families and physicians are transitioning patients from prednisone or deflazacort to vamorolone for the improved side effect profile. The switch should be managed by a neuromuscular specialist. The FDA label says patients can switch from prednisone or deflazacort directly, without a break or a taper first, starting at 6 mg/kg/day.

The VISION-DMD Phase 2b trial compared vamorolone at 6 mg/kg/day to prednisone and placebo. Compared with placebo at 24 weeks, vamorolone 6 mg/kg/day improved time to stand, 6-minute walk distance, and time to run or walk 10 meters. The prednisone group was a reference, and the trial was not designed to show that vamorolone works as well as prednisone. Height percentile and bone turnover markers fell in boys on prednisone but not in boys on vamorolone. The FDA label still lists steroid warnings, including bone loss, mood and behavior changes, and adrenal suppression.

Yes. Vamorolone (Agamree) is approved for patients aged 2 and older with DMD. It comes as an oral liquid suspension, which makes dosing easy for young children. Weight-based dosing at 6 mg/kg/day is taken once daily, preferably with a meal. Store unopened bottles at room temperature. After opening, keep the bottle upright in the refrigerator, and throw away any medicine left 3 months after first opening.

Some steroid-related effects can still occur, including cushingoid appearance, weight gain, increased appetite, and adrenal suppression. However, these tend to be milder than with traditional steroids. The key advantages of vamorolone are better preservation of bone density and growth velocity, and fewer behavioral and mood changes. Vamorolone is not steroid-free; it is a modified steroid designed to reduce the most problematic side effects while maintaining efficacy.